BioGaia ABBGLAF 100 Market Cap is $1,232.9 Mil as of Jun. 28, 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 1,023 Drug Manufacturers companies, BioGaia AB ranks better than 79.57% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioGaia AB's share price for the quarter that ended in Mar. 2026 was $11.7925. BioGaia AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 101.2 Mil. Therefore, BioGaia AB's market cap for the quarter that ended in Mar. 2026 was $1,193.0 Mil.
BioGaia AB's quarterly market cap
increased
from Sep. 2025 ($1,054.1 Mil) to Dec. 2025 ($1,107.7 Mil) and
increased
from Dec. 2025 ($1,107.7 Mil) to Mar. 2026 ($1,193.0 Mil).
BioGaia AB's annual market cap
declined
from Dec. 2023 ($1,005.8 Mil) to Dec. 2024 ($969.1 Mil) but then
increased
from Dec. 2024 ($969.1 Mil) to Dec. 2025 ($1,107.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioGaia AB's Enterprise Value for Today is $1,143.4 Mil.
BioGaia AB (OTCPK:BGLAF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioGaia AB Market Cap Related Terms
BioGaia AB Market Cap Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Market Cap distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioGaia AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Market Cap of $1,232.9 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioGaia AB and its competitors. According to the industry distribution chart, BioGaia AB ranks #209 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is BioGaia AB's Market Cap too high?
BioGaia AB's current Market Cap is $1,232.9 Mil. The Drug Manufacturers industry median Market Cap is 205.37. BioGaia AB's value of $1,232.9 Mil is 500.3% above this industry median. Based on the distribution chart, BioGaia AB ranks #209 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #209 out of 1023 companies for Market Cap. This places BioGaia AB in the top 20% of its industry — outperforming the majority of peers. The industry median Market Cap is 205.37. BioGaia AB's value of $1,232.9 Mil is 500.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Market Cap of $1,232.9 Mil is 500.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Market Cap is $1,232.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Market Cap of $1,232.9 Mil. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Market Cap is $1,232.9 Mil and 500.3% above the Drug Manufacturers industry median of 205.37. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Market Cap is $1,232.9 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
Market Cap: $1,232.9 Mil
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 500.3% above the Drug Manufacturers median (#209 of 1023)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
